|
May 04, 2012, 12.27 PM IST
Shrikant Chauhan of Kotak Securities feels that one should sell Sun Pharma.
Chauhan told CNBC-Awaaz, "One can sell Sun Pharma with one month view. The stoploss should keep at Rs 600. We can see level of Rs 560 at down side."
The company's trailing 12-month (TTM) EPS was at Rs 13.36 per share. (Dec, 2011). The stock's price-to-earnings (P/E) ratio was 44.90. The latest book value of the company is Rs 64.51 per share. At current value, the price-to-book value of the company was 9.3. The dividend yield of the company was 0.58%.
Related News Set email alert for |
Action in Sun Pharmaceutical Industries
 From DJ EU Officials Spain Aid Cap Of 100 Bn Euros 'should Be Enough'  The latest earning numbers FIRST on CNBC-TV18
News Videos
|
